44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow™

44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow™ is organized by Physicians' Education Resource, LLC (PER) and will be held from Nov 11 - 13, 2026 at New York Hilton Midtown, New York City, New York, United States of America.

Description:
Now in its 44th year, the Chemotherapy Foundation Symposium (CFS®) brings together thousands of health care professionals for an exciting 3-day conference that promotes the delivery of evidence-based, state-of-the-art cancer care. Internationally renowned faculty will provide you with expert insights on the latest developments in cancer therapeutics, offering a unique opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize clinical care for your patients with cancer.

Exciting new developments and rapid changes continue to occur in the management of solid and hematologic malignancies. In the past year, practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, and many more are poised to do so. Optimized testing and treatments for early and advanced disease, including chemotherapeutics, targeted therapies, immunotherapies - alone and in combination - and multimodal strategies continue to improve clinical outcomes. CFS® offers you the critical knowledge you need to safely and effectively integrate these strategies into your practice.

Learning Objectives:
Upon completion of this activity, learners will be better able to:

1. Describe the supporting evidence for novel biomarker-testing approaches that guide the use of targeted therapies and/or modification of treatment plans
2. Evaluate efficacy and safety data from recent pivotal trials investigating new and emerging therapies
3. Develop personalized treatment plans based on evolving evidence, guideline recommendations, and individual patient/disease characteristics
4. Apply strategies to identify and mitigate treatment-related adverse effects associated with novel therapies and combination regimens